Trial

• Soligenix's HyBryte for cutaneous T-cell lymphoma (CTCL) has a second Phase 3 trial underway with enrollment of approximately 80 subjects, interim analysis in Q2 2026, and top-line results in H2 2026. • Previous Phase 3 trials showed statistical significance in primary endpoints across multiple cycles, following FDA NDA submission and RTF letter. • The program targets unmet needs in rare dermatological cancers with ongoing FDA discussions for development path.

Exclusive: Justice Jim Henry published data from his own court revealing recent cases took more than a year to reach committalGet our breaking news email, free app or daily news podcastA Queensland supreme court judge says serious criminal cases are taking “excruciatingly longer” to finalise due to “glacial” delays in the state’s magistrates court, where some matters are spending several years in procedural limbo.Justice Jim Henry, who is based at the supreme court in Cairns, published data from his own court revealing that of 31 recent criminal cases he finalised between November and February, on average each case took more than a year (370 days) in the lower courts before a committal. Continue reading...

New York-based Gao Zhen was detained in 2024 during a family visit to China and then tried for ‘defaming national heroes’ The Chinese dissident artist Gao Zhen, known for making satirical sculptures of China’s former leader Mao Zedong, has been tried over accusations of “defaming national heroes and martyrs”, his wife and a rights group have said.Gao, 69, who was detained in 2024 during a visit to China from the US, faces a maximum three-year prison sentence, his wife, Zhao Yaliang, and Shane Yi, a researcher at the Chinese human rights defenders group, said. Continue reading...

Twenty-two defendants, including intelligence agents and police, accused of committing crimes on behalf of Freemason mafiaTwenty-two people are to stand trial in France from Monday on charges of murder and other serious crimes centred on a masonic lodge accused of running hit squads.Seven defendants – including former intelligence agents, soldiers and businessmen – face possible life sentences. Prosecutors allege the group carried out murder, attempted murder, aggravated assault and criminal conspiracy on behalf of a mafia network inside the Athanor lodge in the Paris suburb of Puteaux. Continue reading...

Experts say verdict gives Trump officials scope to crack down on leftwing views using spurious ‘terrorism’ labelThe conviction in Texas of nine activists on terrorism and other charges earlier this month sets an alarming precedent: the Trump administration can crack down on leftwing groups and label them “domestic terrorists”.The case was widely seen as a major test of the Trump administration’s efforts to punish protesters and leftwing views. The charges came after a protest outside of an ICE facility outside of Fort Worth last year. Activists planned to set off fireworks outside of the facility in solidarity with those detained inside, traveling with a cache of automatic weapons and body armor they said was for self-defense against counter-protesters. Once they got there, a small group broke away and began vandalizing cars in the parking lot, spray painting graffiti, slashing tires on a government van, and breaking a security camera. A police officer arrived on the scene and drew his weapon at those in the parking lot, one of the activists opened fire with an AR-15 and hit the police officer in the shoulder. He ultimately survived. Continue reading...

Sewell pleaded not guilty to five charges over alleged group assault on Camp Sovereignty last yearFollow our Australia news live blog for latest updatesGet our breaking news email, free app or daily news podcastNeo-Nazi figure Thomas Sewell has been committed to stand trial after allegedly leading an attack on an Indigenous protest site in Melbourne last year.Sewell, 33, appeared into Melbourne magistrates court via video link on Thursday morning after being charged over the Camp Sovereignty incident. Continue reading...

• HHS through the National Cancer Institute announced a $200 million public-private partnership to fund clinical trials for cancer vaccines targeting high-risk recurrence patients. • The initiative supports mRNA and other vaccine types, aiming to accelerate development with private sector involvement including venture capital. • 'Nothing of this scale has been attempted in cancer vaccines before,' said Stacey Adam, VP of science partnerships for the Foundation for the National Institutes of Health.